Candel Therapeutics (CADL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.36
- Estimate
- -$0.23
- Surprise
- -52.9%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Candel Therapeutics (CADL) reported a wider loss than forecast — diluted EPS of -$0.36 against the -$0.23 estimate (a 52.9% shortfall).
Coverage in the report window
- B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12 — benzinga, 2026-08-14
- HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target — benzinga, 2026-08-13
- Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates CADL Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -52.9% surprise compares with a -14.2% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: aglatimagene
- Quality below floor (1.5 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin 0.2%), Material insider selling (13 sells, 0.43% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.10
- Price target
- $18.27
- Stop
- $12.21
- Upside to target
- +39.5%
- Reward-to-risk
- 2.6:1
Risk check: RSI 75 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
CADL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.00B
- P/E (fwd)
- -21.0
- 52-week range
- $4.35–$13.82
- Off 52-week high
- 5.2%
- RSI (14)
- 75
- Volume vs avg
- 1.01×
- Score today
- 5.2/10